• Share
  • Email
  • Print

Bojan Savic

Partner (German Patent Attorney, European Patent Attorney, European Patent Litigator)
+1.49.89.321.215.439
Fax +49.(0)89.321.215.499
Dr. Bojan Savic has more than 20 years of experience in the field of intellectual property. In addition to being a partner at K&L Gates’ Munich office, he is a German and European Patent Attorney, as well as a European Patent Litigator.

His areas of practice include patent prosecution, opposition and appeal proceedings, patent invalidation, and patent infringement, patent portfolio creation, strategic counseling, and due diligence. He also advises clients with respect to patent term extensions (supplementary protection certificates – SPCs) for medicinal and plant protection products within the European Union.

He possesses vast technical knowledge in the areas of life sciences, pharmaceuticals, and organic chemistry.

Professional Background

Prior to joining K&L Gates in April 2018, Dr. Bojan Savic was a partner at an international law firm.

Professional/Civic Activities

  • German Chemical Society
  • American Chemical Society
  • German Association for the Protection of Intellectual Property (GRUR)
  • Association of Intellectual Property Experts (VPP)
  • Licensing Executives Society (LES)
  • European Patent Litigators’ Association

Speaking Engagements

  • Cross-border IP litigation in the U.S. and Europe: Strategic options for validity and infringement, VPP half-day seminar, Ulm, Germany, October 27, 2016
  • The Unitary Patent and the Unified Patent Court, Philadelphia, Pennsylvania, February 24, 2016
Publications
Mr. Savic is the author of numerous commentaries regarding the case law of the European Patent Office and the CJEU regarding SPCs.
Among others, Mr. Savic has advised and/or represented:
  • Puma Biotechnology, Inc. in European opposition proceedings initiated by Hexal to defend a patent licensed from Pfizer covering Neratinib extended adjuvant therapy for HER2+ breast cancer. The patent was upheld without amendments.
  • Total on the $3.2 billion sale of specialty chemical affiliate Atotech B.V., a global manufacturer of high technology plating solutions, to The Carlyle Group.
  • Akebia Therapeutics, Inc. in successfully challenging the validity of European Patent No. EP1463823 issued to FibroGen, Inc. in opposition proceedings before the European Patent Office.
  • Celgene Corporation on building patent portfolios for various marketed products.